Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2

New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for...

Full description

Saved in:
Bibliographic Details
Published innpj vaccines Vol. 6; no. 1; pp. 156 - 13
Main Authors Lassaunière, Ria, Polacek, Charlotta, Gram, Gregers J., Frische, Anders, Tingstedt, Jeanette Linnea, Krüger, Maren, Dorner, Brigitte G., Cook, Anthony, Brown, Renita, Orekov, Tatyana, Putmon-Taylor, Tammy, Campbell, Tracey-Ann, Greenhouse, Jack, Pessaint, Laurent, Andersen, Hanne, Lewis, Mark G., Fomsgaard, Anders
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 20.12.2021
Nature Publishing Group
Nature Portfolio
Subjects
631/250/590/1991
631/326/596/4130
631/61/24/590/1991
Biomedical and Life Sciences
Biomedicine
COVID-19
COVID-19 vaccines
Deoxyribonucleic acid
DNA
Immunization
Immunogenicity
Infectious Diseases
Medical Microbiology
Public Health
Severe acute respiratory syndrome coronavirus 2
Vaccine
Vaccines
Virology
Online AccessGet full text

Cover

Abstract New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.
AbstractList New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.
New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.
Abstract New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.
ArticleNumber 156
Author Greenhouse, Jack
Brown, Renita
Fomsgaard, Anders
Cook, Anthony
Lassaunière, Ria
Andersen, Hanne
Lewis, Mark G.
Tingstedt, Jeanette Linnea
Polacek, Charlotta
Pessaint, Laurent
Putmon-Taylor, Tammy
Gram, Gregers J.
Frische, Anders
Orekov, Tatyana
Krüger, Maren
Campbell, Tracey-Ann
Dorner, Brigitte G.
Author_xml – sequence: 1
  givenname: Ria
  orcidid: 0000-0002-3910-7185
  surname: Lassaunière
  fullname: Lassaunière, Ria
  organization: Department of Virus and Microbiological Special Diagnostic, Statens Serum Institut
– sequence: 2
  givenname: Charlotta
  surname: Polacek
  fullname: Polacek, Charlotta
  organization: Department of Virus and Microbiological Special Diagnostic, Statens Serum Institut
– sequence: 3
  givenname: Gregers J.
  surname: Gram
  fullname: Gram, Gregers J.
  organization: Department of Business Support and Campus, Statens Serum Institut
– sequence: 4
  givenname: Anders
  orcidid: 0000-0002-2841-7655
  surname: Frische
  fullname: Frische, Anders
  organization: Department of Virus and Microbiological Special Diagnostic, Statens Serum Institut
– sequence: 5
  givenname: Jeanette Linnea
  surname: Tingstedt
  fullname: Tingstedt, Jeanette Linnea
  organization: Department of Virus and Microbiological Special Diagnostic, Statens Serum Institut
– sequence: 6
  givenname: Maren
  orcidid: 0000-0001-9775-3110
  surname: Krüger
  fullname: Krüger, Maren
  organization: Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute
– sequence: 7
  givenname: Brigitte G.
  orcidid: 0000-0002-5100-2546
  surname: Dorner
  fullname: Dorner, Brigitte G.
  organization: Biological Toxins (ZBS 3), Centre for Biological Threats and Special Pathogens, Robert Koch Institute
– sequence: 8
  givenname: Anthony
  surname: Cook
  fullname: Cook, Anthony
  organization: BIOQUAL Inc
– sequence: 9
  givenname: Renita
  surname: Brown
  fullname: Brown, Renita
  organization: BIOQUAL Inc
– sequence: 10
  givenname: Tatyana
  surname: Orekov
  fullname: Orekov, Tatyana
  organization: BIOQUAL Inc
– sequence: 11
  givenname: Tammy
  surname: Putmon-Taylor
  fullname: Putmon-Taylor, Tammy
  organization: BIOQUAL Inc
– sequence: 12
  givenname: Tracey-Ann
  surname: Campbell
  fullname: Campbell, Tracey-Ann
  organization: BIOQUAL Inc
– sequence: 13
  givenname: Jack
  surname: Greenhouse
  fullname: Greenhouse, Jack
  organization: BIOQUAL Inc
– sequence: 14
  givenname: Laurent
  surname: Pessaint
  fullname: Pessaint, Laurent
  organization: BIOQUAL Inc
– sequence: 15
  givenname: Hanne
  orcidid: 0000-0003-1103-9608
  surname: Andersen
  fullname: Andersen, Hanne
  organization: BIOQUAL Inc
– sequence: 16
  givenname: Mark G.
  orcidid: 0000-0001-7852-0135
  surname: Lewis
  fullname: Lewis, Mark G.
  organization: BIOQUAL Inc
– sequence: 17
  givenname: Anders
  orcidid: 0000-0003-4304-0603
  surname: Fomsgaard
  fullname: Fomsgaard, Anders
  email: afo@ssi.dk
  organization: Department of Virus and Microbiological Special Diagnostic, Statens Serum Institut, Infectious Disease Research Unit, Clinical Institute, University of Southern Denmark
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34930909$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhSNUREvpH2CBIrFhE_AztjdIo-FVqQLUAlvrxnYGDxl7sJOR6K_HnbTQdtGFZSv-zvFR7nlaHYQYXFU9x-g1RlS-yQxzhhtEykIMq-byUXVEEFcNwogf3DofVic5rxFCWLSUC_SkOqRMUaSQOqrOvyZnBh-8gaF2OxgmGH0MdexrqA0E6y2Mrg7wy9l6O0DeeFu_-7yod2CMD66GFfiQx_picX7RLOOPhjyrHvcwZHdyvR9X3z-8_7b81Jx9-Xi6XJw1hjM0Nr3oGLKESyAgBUgjBAOwjBNlKAUQxFFicaeI6S3pqZHCuk5hwY1yTPX0uDqdfW2Etd4mv4H0R0fwev8hppWGNHozOO06bIzolC0PMgyd4kq1sm9bkD1THS9eb2ev7dRtnDUujAmGO6Z3b4L_qVdxp2UrJcOyGLy6Nkjx9-TyqDc-GzcMEFycsiYtJlRh3uKCvryHruOUQvlVVxSWZXCsLdSL24n-RbkZXQHkDJgUc06u18aP--GVgH7QGOmroui5KLoURe-Loi-LlNyT3rg_KKKzKBc4rFz6H_sB1V889s9X
CitedBy_id crossref_primary_10_3390_vaccines10071104
crossref_primary_10_1016_j_isci_2023_107120
crossref_primary_10_1016_j_vaccine_2023_09_021
crossref_primary_10_3390_vaccines11061014
crossref_primary_10_1038_s41598_024_64690_5
crossref_primary_10_3390_vaccines11020376
crossref_primary_10_1186_s12985_023_01974_8
crossref_primary_10_3390_vaccines11091451
crossref_primary_10_3389_fimmu_2023_1200718
crossref_primary_10_1001_jamanetworkopen_2022_12073
crossref_primary_10_1016_j_heliyon_2025_e42533
crossref_primary_10_3390_vaccines12111292
crossref_primary_10_3390_vaccines12030218
crossref_primary_10_1016_j_jconrel_2024_06_013
crossref_primary_10_3389_fbioe_2023_1296444
crossref_primary_10_3390_vaccines11020280
crossref_primary_10_1039_D4PM00009A
crossref_primary_10_1002_jmv_29040
crossref_primary_10_1371_journal_pone_0275082
crossref_primary_10_1038_s41467_024_44830_1
Cites_doi 10.1371/journal.pone.0059340
10.1038/s41586-020-2607-z
10.2807/1560-7917.ES.2021.26.27.2100568
10.1172/JCI128699
10.1126/science.abc5343
10.1136/bmj.n1875
10.1084/jem.20071331
10.1038/s41577-020-00434-6
10.1038/s41586-020-2196-x
10.1586/14760584.7.2.175
10.1038/s41392-020-00372-8
10.1001/jamainternmed.2020.3391
10.3389/fimmu.2018.01568
10.1056/NEJMoa2024671
10.1126/science.aai9137
10.1093/infdis/jir054
10.1016/j.ijpharm.2013.06.010
10.1016/S0140-6736(21)00432-3
10.1016/j.eclinm.2021.101020
10.1056/NEJMoa2034577
10.1016/S1525-0016(16)35125-5
10.1136/jclinpath-2020-206658
10.3390/v13020258
10.1158/1078-0432.CCR-19-1614
10.1126/science.abc4776
10.1016/j.vaccine.2009.02.061
10.1016/j.coi.2009.05.016
10.1128/IAI.69.12.7250-7253.2001
10.1126/science.abc6284
10.1038/s41586-020-2608-y
10.1016/j.micinf.2007.07.009
10.1056/NEJMoa2035389
10.1038/s41392-020-00269-6
10.1128/JVI.02370-20
10.3390/microorganisms9051040
10.1126/sciadv.abe8065
10.1016/j.vaccine.2020.10.064
10.1126/science.abb9983
10.1016/S0140-6736(17)33105-7
10.1126/science.abc1932
10.1128/JVI.01250-10
10.1038/ncomms6317
10.2174/156652321403140819122538
10.1016/j.cell.2020.03.045
10.1126/science.abb8923
10.1038/s41541-020-00279-z
10.1038/s41467-020-15562-9
10.1016/S0022-1759(98)00170-7
10.4161/hv.25048
10.1016/j.xcrm.2021.100420
10.1039/b911525k
ContentType Journal Article
Copyright The Author(s) 2021
2021. The Author(s).
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: 2021. The Author(s).
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7RV
7X7
7XB
88C
8C1
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9-
K9.
KB0
M0R
M0S
M0T
NAPCQ
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41541-021-00419-z
DatabaseName Springer Nature OA Free Journals
CrossRef
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Healthcare Administration Database (Alumni)
Public Health Database
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
ProQuest Health Research Premium Collection
Health Research Premium Collection (Alumni)
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Consumer Health Database
ProQuest Health & Medical Collection
Healthcare Administration Database
ProQuest Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Sustainability
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Public Health
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Health Management
Coronavirus Research Database
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE - Academic
PubMed

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 2059-0105
EndPage 13
ExternalDocumentID oai_doaj_org_article_eb1cc7b9d0d241ab959968f66a8f49b5
PMC8688418
34930909
10_1038_s41541_021_00419_z
Genre Journal Article
GroupedDBID 0R~
53G
5VS
7RV
7X7
8C1
8FI
8FJ
AAJSJ
AASML
ABUWG
ACGFS
ADBBV
AEUYN
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BCNDV
BENPR
C6C
CCPQU
EBLON
EBS
ECGQY
FYUFA
GROUPED_DOAJ
HMCUK
HYE
K9-
KQ8
M0R
M0T
M~E
NAO
NAPCQ
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PUEGO
RNT
RPM
SNYQT
UKHRP
AAYXX
ALIPV
CITATION
NPM
3V.
7XB
8FK
COVID
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c540t-f7b40d258a2a87a8c774aad4529c33aa72e32d1b92cfd2f3c87deb9175c9e49f3
IEDL.DBID DOA
ISSN 2059-0105
IngestDate Wed Aug 27 01:20:48 EDT 2025
Thu Aug 21 13:20:52 EDT 2025
Thu Jul 10 23:54:35 EDT 2025
Sat Jul 26 03:18:27 EDT 2025
Mon Jul 21 06:09:31 EDT 2025
Thu Apr 24 22:50:29 EDT 2025
Tue Jul 01 04:21:14 EDT 2025
Sun Aug 31 08:58:45 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2021. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-f7b40d258a2a87a8c774aad4529c33aa72e32d1b92cfd2f3c87deb9175c9e49f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-3910-7185
0000-0003-4304-0603
0000-0002-2841-7655
0000-0001-7852-0135
0000-0003-1103-9608
0000-0002-5100-2546
0000-0001-9775-3110
OpenAccessLink https://doaj.org/article/eb1cc7b9d0d241ab959968f66a8f49b5
PMID 34930909
PQID 2611820546
PQPubID 4669711
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_eb1cc7b9d0d241ab959968f66a8f49b5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8688418
proquest_miscellaneous_2612391561
proquest_journals_2611820546
pubmed_primary_34930909
crossref_citationtrail_10_1038_s41541_021_00419_z
crossref_primary_10_1038_s41541_021_00419_z
springer_journals_10_1038_s41541_021_00419_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-20
PublicationDateYYYYMMDD 2021-12-20
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-20
  day: 20
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle npj vaccines
PublicationTitleAbbrev npj Vaccines
PublicationTitleAlternate NPJ Vaccines
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Graham (CR40) 2020; 368
Voysey (CR37) 2021; 397
Gao (CR31) 2020; 369
Gaudinski (CR7) 2018; 391
Lee, Izzard, Hurt (CR3) 2018; 9
Zhang (CR22) 2020; 5
Jeyanathan (CR43) 2020; 20
Lu, Wang, Grimes-Serrano (CR48) 2008; 7
Graham (CR16) 2013; 8
Corbett (CR34) 2020; 383
Narum (CR13) 2001; 69
Watanabe, Allen, Wrapp, McLellan, Crispin (CR19) 2020; 369
Deng (CR29) 2020; 369
Harari (CR49) 2008; 205
Chandrashekar (CR23) 2020; 369
Patel (CR27) 2020; 2
Teixeira (CR17) 2020; 26
Yu (CR28) 2020; 369
Wang (CR32) 2020; 181
Polack (CR47) 2020; 383
van der Heijden, Beijnen, Nuijen (CR4) 2013; 453
Klasse, Nixon, Moore (CR39) 2021; 7
CR45
Dagotto (CR24) 2021; 95
Nguyen (CR52) 2021; 26
Brocato (CR41) 2021; 6
Mercado (CR26) 2020; 586
Mahase (CR38) 2021; 374
Ou (CR20) 2020; 11
Williams (CR12) 2014; 14
Lu (CR30) 2020; 5
Baden (CR46) 2020; 384
CR15
Luke (CR14) 2011; 85
Leventhal, Clancy, Erasmus, Feldmann, Hawman (CR42) 2021; 9
Fomsgaard, Liu (CR2) 2021; 13
Nelson, Rodriguez, Finlayson, Williams, Carnes (CR11) 2013; 9
Guebre-Xabier (CR35) 2020; 38
Rouphael (CR5) 2019; 129
Luke (CR18) 2014; 22
Brice (CR36) 2007; 9
van Doremalen (CR33) 2020; 586
Lu (CR50) 2009; 21
Dowd (CR6) 2016; 354
Jones (CR9) 2009; 27
Pauly (CR51) 2009; 134
Kim (CR10) 2014; 5
Wölfel (CR25) 2020; 581
Momin (CR44) 2021; 38
Ledgerwood (CR8) 2011; 203
Pillay (CR21) 2020; 73
Frey, Di Canzio, Zurakowski (CR53) 1998; 221
Weinberger (CR1) 2020; 180
A Fomsgaard (419_CR2) 2021; 13
BS Graham (419_CR16) 2013; 8
S Jones (419_CR9) 2009; 27
SS Leventhal (419_CR42) 2021; 9
T Momin (419_CR44) 2021; 38
S Lu (419_CR48) 2008; 7
A Patel (419_CR27) 2020; 2
J Luke (419_CR18) 2014; 22
I van der Heijden (419_CR4) 2013; 453
X Ou (419_CR20) 2020; 11
Y Watanabe (419_CR19) 2020; 369
D Nguyen (419_CR52) 2021; 26
M Guebre-Xabier (419_CR35) 2020; 38
DM Weinberger (419_CR1) 2020; 180
JA Williams (419_CR12) 2014; 14
A Chandrashekar (419_CR23) 2020; 369
S Lu (419_CR30) 2020; 5
E Mahase (419_CR38) 2021; 374
LR Baden (419_CR46) 2020; 384
A Frey (419_CR53) 1998; 221
R Wölfel (419_CR25) 2020; 581
BS Graham (419_CR40) 2020; 368
M Jeyanathan (419_CR43) 2020; 20
G Dagotto (419_CR24) 2021; 95
NG Rouphael (419_CR5) 2019; 129
DL Narum (419_CR13) 2001; 69
A Harari (419_CR49) 2008; 205
MR Gaudinski (419_CR7) 2018; 391
TJ Kim (419_CR10) 2014; 5
419_CR15
W Deng (419_CR29) 2020; 369
GT Brice (419_CR36) 2007; 9
L Teixeira (419_CR17) 2020; 26
FP Polack (419_CR47) 2020; 383
S Lu (419_CR50) 2009; 21
PJ Klasse (419_CR39) 2021; 7
LYY Lee (419_CR3) 2018; 9
KS Corbett (419_CR34) 2020; 383
JE Ledgerwood (419_CR8) 2011; 203
419_CR45
KA Dowd (419_CR6) 2016; 354
JM Luke (419_CR14) 2011; 85
J Zhang (419_CR22) 2020; 5
NB Mercado (419_CR26) 2020; 586
J Yu (419_CR28) 2020; 369
Q Gao (419_CR31) 2020; 369
Q Wang (419_CR32) 2020; 181
TS Pillay (419_CR21) 2020; 73
D Pauly (419_CR51) 2009; 134
J Nelson (419_CR11) 2013; 9
RL Brocato (419_CR41) 2021; 6
M Voysey (419_CR37) 2021; 397
N van Doremalen (419_CR33) 2020; 586
References_xml – volume: 8
  start-page: e59340
  year: 2013
  ident: CR16
  article-title: DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-Cell responses after rAd5 boost in a randomized clinical trial
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0059340
– ident: CR45
– volume: 586
  start-page: 583
  year: 2020
  end-page: 588
  ident: CR26
  article-title: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
  publication-title: Nature
  doi: 10.1038/s41586-020-2607-z
– volume: 26
  start-page: 2100568
  year: 2021
  ident: CR52
  article-title: SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
  publication-title: Eurosurveillance
  doi: 10.2807/1560-7917.ES.2021.26.27.2100568
– volume: 129
  start-page: 4769
  year: 2019
  end-page: 4785
  ident: CR5
  article-title: DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI128699
– volume: 369
  start-page: 818
  year: 2020
  end-page: 823
  ident: CR29
  article-title: Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
  publication-title: Science
  doi: 10.1126/science.abc5343
– volume: 374
  start-page: n1875
  year: 2021
  ident: CR38
  article-title: Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds
  publication-title: BMJ
  doi: 10.1136/bmj.n1875
– volume: 205
  start-page: 63
  year: 2008
  end-page: 77
  ident: CR49
  article-title: An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20071331
– volume: 20
  start-page: 615
  year: 2020
  end-page: 632
  ident: CR43
  article-title: Immunological considerations for COVID-19 vaccine strategies
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-00434-6
– volume: 581
  start-page: 465
  year: 2020
  end-page: 469
  ident: CR25
  article-title: Virological assessment of hospitalized patients with COVID-2019
  publication-title: Nature
  doi: 10.1038/s41586-020-2196-x
– volume: 7
  start-page: 175
  year: 2008
  end-page: 191
  ident: CR48
  article-title: Current progress of DNA vaccine studies in humans
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.7.2.175
– volume: 5
  start-page: 269
  year: 2020
  ident: CR22
  article-title: A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00372-8
– volume: 180
  start-page: 1336
  year: 2020
  end-page: 1344
  ident: CR1
  article-title: Estimation of excess deaths associated with the COVID-19 pandemic in the United States, March to May 2020
  publication-title: JAMA Intern. Med.
  doi: 10.1001/jamainternmed.2020.3391
– volume: 9
  start-page: 1568
  year: 2018
  ident: CR3
  article-title: A review of DNA vaccines against influenza
  publication-title: Front. Immunol
  doi: 10.3389/fimmu.2018.01568
– volume: 383
  start-page: 1544
  year: 2020
  end-page: 1555
  ident: CR34
  article-title: Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2024671
– ident: CR15
– volume: 354
  start-page: 237
  year: 2016
  end-page: 240
  ident: CR6
  article-title: Rapid development of a DNA vaccine for Zika virus
  publication-title: Science
  doi: 10.1126/science.aai9137
– volume: 203
  start-page: 1396
  year: 2011
  end-page: 1404
  ident: CR8
  article-title: A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jir054
– volume: 453
  start-page: 648
  year: 2013
  end-page: 650
  ident: CR4
  article-title: Long term stability of lyophilized plasmid DNA pDERMATT
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2013.06.010
– volume: 397
  start-page: 881
  year: 2021
  end-page: 891
  ident: CR37
  article-title: Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00432-3
– volume: 38
  start-page: 101020
  year: 2021
  ident: CR44
  article-title: Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.101020
– volume: 383
  start-page: 2603
  year: 2020
  end-page: 2615
  ident: CR47
  article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2034577
– volume: 22
  start-page: S42
  year: 2014
  ident: CR18
  article-title: Novel nonviral plasmid vectors with minimalized bacterial backbones dramatically increase transgene expression level in vivo
  publication-title: Mol. Ther.
  doi: 10.1016/S1525-0016(16)35125-5
– volume: 73
  start-page: 366
  year: 2020
  end-page: 369
  ident: CR21
  article-title: Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein
  publication-title: J. Clin. Pathol
  doi: 10.1136/jclinpath-2020-206658
– volume: 13
  start-page: 258
  year: 2021
  ident: CR2
  article-title: The key role of nucleic acid vaccines for one health
  publication-title: Viruses
  doi: 10.3390/v13020258
– volume: 26
  start-page: 588
  year: 2020
  end-page: 597
  ident: CR17
  article-title: A first-in-human phase I study of INVAC-1, an optimized human telomerase DNA vaccine in patients with advanced solid tumors
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-1614
– volume: 369
  start-page: 812
  year: 2020
  end-page: 817
  ident: CR23
  article-title: SARS-CoV-2 infection protects against rechallenge in rhesus macaques
  publication-title: Science
  doi: 10.1126/science.abc4776
– volume: 27
  start-page: 2506
  year: 2009
  end-page: 2512
  ident: CR9
  article-title: DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.02.061
– volume: 21
  start-page: 346
  year: 2009
  end-page: 351
  ident: CR50
  article-title: Heterologous prime–boost vaccination
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2009.05.016
– volume: 69
  start-page: 7250
  year: 2001
  end-page: 7253
  ident: CR13
  article-title: Codon optimization of gene fragments encoding Plasmodium falciparum Merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice
  publication-title: Infect. Immun.
  doi: 10.1128/IAI.69.12.7250-7253.2001
– volume: 369
  start-page: 806
  year: 2020
  end-page: 811
  ident: CR28
  article-title: DNA vaccine protection against SARS-CoV-2 in rhesus macaques
  publication-title: Science
  doi: 10.1126/science.abc6284
– volume: 586
  start-page: 578
  year: 2020
  end-page: 582
  ident: CR33
  article-title: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
  publication-title: Nature
  doi: 10.1038/s41586-020-2608-y
– volume: 9
  start-page: 1439
  year: 2007
  end-page: 1446
  ident: CR36
  article-title: Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines
  publication-title: Microbes Infect.
  doi: 10.1016/j.micinf.2007.07.009
– volume: 384
  start-page: 403
  year: 2020
  end-page: 416
  ident: CR46
  article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2035389
– volume: 5
  start-page: 157
  year: 2020
  ident: CR30
  article-title: Comparison of nonhuman primates identified the suitable model for COVID-19
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00269-6
– volume: 95
  start-page: e02370
  year: 2021
  end-page: 02320
  ident: CR24
  article-title: Comparison of subgenomic and total RNA in SARS-CoV-2-challenged rhesus macaques
  publication-title: J. Virol.
  doi: 10.1128/JVI.02370-20
– volume: 9
  start-page: 1040
  year: 2021
  ident: CR42
  article-title: An intramuscular DNA vaccine for SARS-CoV-2 decreases viral lung load but not lung pathology in Syrian hamsters
  publication-title: Microorganisms
  doi: 10.3390/microorganisms9051040
– volume: 7
  start-page: eabe8065
  year: 2021
  ident: CR39
  article-title: Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abe8065
– volume: 38
  start-page: 7892
  year: 2020
  end-page: 7896
  ident: CR35
  article-title: NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2020.10.064
– volume: 369
  start-page: 330
  year: 2020
  end-page: 333
  ident: CR19
  article-title: Site-specific glycan analysis of the SARS-CoV-2 spike
  publication-title: Science
  doi: 10.1126/science.abb9983
– volume: 391
  start-page: 552
  year: 2018
  end-page: 562
  ident: CR7
  article-title: Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)33105-7
– volume: 369
  start-page: 77
  year: 2020
  end-page: 81
  ident: CR31
  article-title: Development of an inactivated vaccine candidate for SARS-CoV-2
  publication-title: Science
  doi: 10.1126/science.abc1932
– volume: 85
  start-page: 1370
  year: 2011
  end-page: 1383
  ident: CR14
  article-title: Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine
  publication-title: J. Virol.
  doi: 10.1128/JVI.01250-10
– volume: 5
  year: 2014
  ident: CR10
  article-title: Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms6317
– volume: 14
  start-page: 170
  year: 2014
  end-page: 189
  ident: CR12
  article-title: Improving DNA vaccine performance through vector design
  publication-title: Curr. Gene Ther.
  doi: 10.2174/156652321403140819122538
– volume: 181
  start-page: 894
  year: 2020
  end-page: 904
  ident: CR32
  article-title: Structural and functional basis of SARS-CoV-2 entry by using human ACE2
  publication-title: Cell
  doi: 10.1016/j.cell.2020.03.045
– volume: 368
  start-page: 945
  year: 2020
  end-page: 946
  ident: CR40
  article-title: Rapid COVID-19 vaccine development
  publication-title: Science
  doi: 10.1126/science.abb8923
– volume: 6
  year: 2021
  ident: CR41
  article-title: Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
  publication-title: npj Vaccines
  doi: 10.1038/s41541-020-00279-z
– volume: 11
  year: 2020
  ident: CR20
  article-title: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-15562-9
– volume: 221
  start-page: 35
  year: 1998
  end-page: 41
  ident: CR53
  article-title: A statistically defined endpoint titer determination method for immunoassays
  publication-title: J. Immunological Methods
  doi: 10.1016/S0022-1759(98)00170-7
– volume: 9
  start-page: 2211
  year: 2013
  end-page: 2215
  ident: CR11
  article-title: Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process
  publication-title: Hum. Vaccines Immunother.
  doi: 10.4161/hv.25048
– volume: 2
  start-page: 100420
  year: 2020
  ident: CR27
  article-title: Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
  publication-title: Cell Rep. Med
  doi: 10.1016/j.xcrm.2021.100420
– volume: 134
  start-page: 2028
  year: 2009
  end-page: 2039
  ident: CR51
  article-title: Simultaneous quantification of five bacterial and plant toxins from complex matrices using a multiplexed fluorescent magnetic suspension assay
  publication-title: Analyst
  doi: 10.1039/b911525k
– ident: 419_CR15
– volume: 9
  start-page: 1568
  year: 2018
  ident: 419_CR3
  publication-title: Front. Immunol
  doi: 10.3389/fimmu.2018.01568
– volume: 397
  start-page: 881
  year: 2021
  ident: 419_CR37
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00432-3
– volume: 27
  start-page: 2506
  year: 2009
  ident: 419_CR9
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.02.061
– volume: 69
  start-page: 7250
  year: 2001
  ident: 419_CR13
  publication-title: Infect. Immun.
  doi: 10.1128/IAI.69.12.7250-7253.2001
– volume: 586
  start-page: 578
  year: 2020
  ident: 419_CR33
  publication-title: Nature
  doi: 10.1038/s41586-020-2608-y
– volume: 203
  start-page: 1396
  year: 2011
  ident: 419_CR8
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jir054
– volume: 26
  start-page: 588
  year: 2020
  ident: 419_CR17
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-1614
– volume: 384
  start-page: 403
  year: 2020
  ident: 419_CR46
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2035389
– volume: 374
  start-page: n1875
  year: 2021
  ident: 419_CR38
  publication-title: BMJ
  doi: 10.1136/bmj.n1875
– volume: 7
  start-page: eabe8065
  year: 2021
  ident: 419_CR39
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abe8065
– ident: 419_CR45
– volume: 369
  start-page: 77
  year: 2020
  ident: 419_CR31
  publication-title: Science
  doi: 10.1126/science.abc1932
– volume: 7
  start-page: 175
  year: 2008
  ident: 419_CR48
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.7.2.175
– volume: 9
  start-page: 1439
  year: 2007
  ident: 419_CR36
  publication-title: Microbes Infect.
  doi: 10.1016/j.micinf.2007.07.009
– volume: 453
  start-page: 648
  year: 2013
  ident: 419_CR4
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2013.06.010
– volume: 383
  start-page: 1544
  year: 2020
  ident: 419_CR34
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2024671
– volume: 13
  start-page: 258
  year: 2021
  ident: 419_CR2
  publication-title: Viruses
  doi: 10.3390/v13020258
– volume: 129
  start-page: 4769
  year: 2019
  ident: 419_CR5
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI128699
– volume: 391
  start-page: 552
  year: 2018
  ident: 419_CR7
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)33105-7
– volume: 180
  start-page: 1336
  year: 2020
  ident: 419_CR1
  publication-title: JAMA Intern. Med.
  doi: 10.1001/jamainternmed.2020.3391
– volume: 134
  start-page: 2028
  year: 2009
  ident: 419_CR51
  publication-title: Analyst
  doi: 10.1039/b911525k
– volume: 586
  start-page: 583
  year: 2020
  ident: 419_CR26
  publication-title: Nature
  doi: 10.1038/s41586-020-2607-z
– volume: 368
  start-page: 945
  year: 2020
  ident: 419_CR40
  publication-title: Science
  doi: 10.1126/science.abb8923
– volume: 369
  start-page: 806
  year: 2020
  ident: 419_CR28
  publication-title: Science
  doi: 10.1126/science.abc6284
– volume: 95
  start-page: e02370
  year: 2021
  ident: 419_CR24
  publication-title: J. Virol.
  doi: 10.1128/JVI.02370-20
– volume: 181
  start-page: 894
  year: 2020
  ident: 419_CR32
  publication-title: Cell
  doi: 10.1016/j.cell.2020.03.045
– volume: 581
  start-page: 465
  year: 2020
  ident: 419_CR25
  publication-title: Nature
  doi: 10.1038/s41586-020-2196-x
– volume: 205
  start-page: 63
  year: 2008
  ident: 419_CR49
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20071331
– volume: 369
  start-page: 818
  year: 2020
  ident: 419_CR29
  publication-title: Science
  doi: 10.1126/science.abc5343
– volume: 85
  start-page: 1370
  year: 2011
  ident: 419_CR14
  publication-title: J. Virol.
  doi: 10.1128/JVI.01250-10
– volume: 22
  start-page: S42
  year: 2014
  ident: 419_CR18
  publication-title: Mol. Ther.
  doi: 10.1016/S1525-0016(16)35125-5
– volume: 38
  start-page: 101020
  year: 2021
  ident: 419_CR44
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.101020
– volume: 369
  start-page: 330
  year: 2020
  ident: 419_CR19
  publication-title: Science
  doi: 10.1126/science.abb9983
– volume: 14
  start-page: 170
  year: 2014
  ident: 419_CR12
  publication-title: Curr. Gene Ther.
  doi: 10.2174/156652321403140819122538
– volume: 2
  start-page: 100420
  year: 2020
  ident: 419_CR27
  publication-title: Cell Rep. Med
  doi: 10.1016/j.xcrm.2021.100420
– volume: 369
  start-page: 812
  year: 2020
  ident: 419_CR23
  publication-title: Science
  doi: 10.1126/science.abc4776
– volume: 38
  start-page: 7892
  year: 2020
  ident: 419_CR35
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2020.10.064
– volume: 5
  start-page: 157
  year: 2020
  ident: 419_CR30
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00269-6
– volume: 383
  start-page: 2603
  year: 2020
  ident: 419_CR47
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2034577
– volume: 221
  start-page: 35
  year: 1998
  ident: 419_CR53
  publication-title: J. Immunological Methods
  doi: 10.1016/S0022-1759(98)00170-7
– volume: 73
  start-page: 366
  year: 2020
  ident: 419_CR21
  publication-title: J. Clin. Pathol
  doi: 10.1136/jclinpath-2020-206658
– volume: 6
  year: 2021
  ident: 419_CR41
  publication-title: npj Vaccines
  doi: 10.1038/s41541-020-00279-z
– volume: 9
  start-page: 1040
  year: 2021
  ident: 419_CR42
  publication-title: Microorganisms
  doi: 10.3390/microorganisms9051040
– volume: 5
  start-page: 269
  year: 2020
  ident: 419_CR22
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00372-8
– volume: 21
  start-page: 346
  year: 2009
  ident: 419_CR50
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/j.coi.2009.05.016
– volume: 11
  year: 2020
  ident: 419_CR20
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-15562-9
– volume: 26
  start-page: 2100568
  year: 2021
  ident: 419_CR52
  publication-title: Eurosurveillance
  doi: 10.2807/1560-7917.ES.2021.26.27.2100568
– volume: 5
  year: 2014
  ident: 419_CR10
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms6317
– volume: 8
  start-page: e59340
  year: 2013
  ident: 419_CR16
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0059340
– volume: 9
  start-page: 2211
  year: 2013
  ident: 419_CR11
  publication-title: Hum. Vaccines Immunother.
  doi: 10.4161/hv.25048
– volume: 20
  start-page: 615
  year: 2020
  ident: 419_CR43
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-00434-6
– volume: 354
  start-page: 237
  year: 2016
  ident: 419_CR6
  publication-title: Science
  doi: 10.1126/science.aai9137
SSID ssj0001763570
Score 2.2890391
Snippet New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying...
Abstract New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens....
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 156
SubjectTerms 631/250/590/1991
631/326/596/4130
631/61/24/590/1991
Biomedical and Life Sciences
Biomedicine
COVID-19
COVID-19 vaccines
Deoxyribonucleic acid
DNA
Immunization
Immunogenicity
Infectious Diseases
Medical Microbiology
Public Health
Severe acute respiratory syndrome coronavirus 2
Vaccine
Vaccines
Virology
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bbxQhFCZaX3wx9T61GkxMX1xSBhgGnsxabRoTm00vZt8It6kbdWbtbk3aXy8w7E7WSx_mZYAEOBcO53C-A8AbaU0jK0oQJ5YjpgMbCyk0csxHaBdJrI8O_c_H_OicfZpW0-xwW-RnlSudmBS162z0ke8HSz9ijVeMv5v_RLFqVIyu5hIad8G9CF0Wubqe1oOPJaGt4Zwrg6nYX4TzioX7MwkfZqVENxvnUYLt_5et-feTyT_ipuk4OtwGD7IdCcc94R-CO759BPYmPRD19QieDXlVixHcg5MBovr6MTiZBEWXcyLhAPgNuwZqaGOmS3QEwFZ_8w7Og4H9Y-bgh-Mx_KVtjMRDfaFnwbCEp-OTU3TQfUHkCTg__Hh2cIRydQVkg5W2RE1tGHakEpoECmlhgyGotYuBWEup1jXxlLjSBHI1jjTUitp5E253lZWeyYY-BVtt1_rnAFbCa156yZjRzFfMYGbCcIy1xdxgV4BytcfKZujxWAHju0ohcCpUTxcV6KISXdRNAd6ux8x74I1be7-PpFv3jKDZ6Ud3eaGyDKpwLFlbG-nCslmpjYzQNKLhXIuGSVMVYHdFeJUleaEGvivA63VzkMEYWNGt765SHxKB9nlZgGc9n6xnQpmkWGJZgHqDgzamutnSzr4mnG_BhWClKMBoxWvDtP6_FTu3r-IFuE8i-5ckKMhdsLW8vPIvg121NK-S8PwGjSMfmA
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9QwDLfG9oKEJhhfHQMFCe2Fq0iTtJc8lsE0ncR02m1ob1WSptsJaKfdDWn763HS9qqDgcRDX1pHcmM7duz4F4B3yppKpZzFGbNZLDSqsVRSx6VwHtpFMet8Qv_LcXZ0Jibn6fkGsL4XJhzaD5CWYZnuT4d9WKCjEbjxZfhQkaj47gFseah21O2tPJ_MJkNmJWCs0a5DhnJ5z-A1LxTA-u-LMP88KPlbtTQ4ocPHsN1FjyRv-X0CG67egf1pCz99OyKnQzfVYkT2yXQApr7dgUdtjo60rUdP4WSKy13XGUkG2G_SVEQT6_tdfDqA1PqbK8kVhtk_5iX5dJyTn9r6ejzRF3qO4SWZ5Sez-KD5GrNncHb4-fTgKO7uWIgtxmrLuBobQUuWSs1QTlpaDAe1Ln051nKu9Zg5zsrEoNCqklXcynHpDO7xUqucUBV_Dpt1U7uXQFLpdJY4JYTRwqXCUGFwOKXa0szQMoKkn_PCdgDk_h6M70UohHNZtHIqUE5FkFNxF8H71ZirFn7jn9QfvShXlB46O7xori-KTpUKdE7Wjo0q8bdFoo3yADWyyjItK6FMGsFerwhFZ8-LAveZHuk-FVkEb1ef0RJ9eUXXrrkJNMzD7WdJBC9avVlxwoXiVFEVwXhNo9ZYXf9Szy8D2rfMpBSJjGDU697A1t-nYvf_yF_BQ-bNI2G4bO7B5vL6xr3GaGtp3nTm9QtWdiQq
  priority: 102
  providerName: Springer Nature
Title Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
URI https://link.springer.com/article/10.1038/s41541-021-00419-z
https://www.ncbi.nlm.nih.gov/pubmed/34930909
https://www.proquest.com/docview/2611820546
https://www.proquest.com/docview/2612391561
https://pubmed.ncbi.nlm.nih.gov/PMC8688418
https://doaj.org/article/eb1cc7b9d0d241ab959968f66a8f49b5
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgvPCCxnfGqIyE9kKjObbj2I9Z2DQVUZV2Q32LbMcZFZBOtEPa_nrOTtqufL7wEEfyh3S6O_vufPbPCL1W1tQqZTQW1IqYa1BjqaSOK-48tIui1vkN_fdDcXrOB9N0euupL38mrIUHbhl3CGuJtZlRFanA2GijPJ6IrIXQsubKBPRSsHm3gqmwuxJw1kh3S4YwebgAS8UhcqbwEZ6o-GbLEgXA_t95mb8elvwpYxoM0ckuetB5kDhvKX-I7rjmEToYtRDU1318trlRtejjAzzagFNfP0bjESxx3W1IvIH6xvMaa2z9HRe_BYAb_dlV-BJc66-zCr8d5vi7tj4Hj_WFnoFLiSf5eBIX848xfYLOT47PitO4e1chtuCfLeM6Mxy4mUpNQTZaWnABta58CtYypnVGHaNVYkBQdUVrZmVWOQNxXWqV46pmT9FOM2_cc4RT6bRInOLcaO5Sbgg3MJwQbYkwpIpQsuJxaTvQcf_2xZcyJL-ZLFu5lCCXMsilvInQm_WYyxZy46-9j7zo1j09XHaoACUqOyUq_6VEEdpfCb7s5vCihNjSo9unXETo1boZZp9PqejGza9CH-oh9kUSoWetnqwpYVwxooiKULalQVukbrc0s08B4VsKKXkiI9Rf6dqGrD-zYu9_sOIFuk_9JEkoLKD7aGf57cq9BL9raXrobjbNoJRF0kP38nwwGcD_6Hg4GkNtIYpemIRQvvsgfwCdoy9s
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOcAF8SZQwEjQCxvVcZysfUBo2VJtabtatVvUm_ErZQUkS3cL2v4ofiPjPDZaHr31kEtiR2PPw2OP5xuEXgqjM5HENEypSUOmQIy54Cq0zHloF0GN8wf6B8N0cMw-nCQna-hXkwvjr1U2NrE01LYw_ox8Czx9jzWesPTt9Hvoq0b56GpTQqMSiz23-Albttmb3W3g7ytKd96P-4OwrioQGvBO5mHW1YxYmnBFgTLFDThASlkfgDRxrFSXupjaSAOZmaVZbHjXOg27msQIx0QWw3-voessBtX0men9qD3TKdHdSJ2bQ2K-NYP1kcF-ncJDWCTCi5X1rywT8C_f9u8rmn_Eacvlb-c2ulX7rbhXCdodtObyu2hzVAFfLzp43OZxzTp4E49aSOzFPXQ4AsNa52DiFmAcFxlW2PjMGn_wgHP1xVk8BYf-28Ti7WEP_1DGR_6xOlUTcGTxUe_wKOwXH0N6Hx1fybw_QOt5kbtHCCfcqTRygjGtmEuYJkxDd0KUIakmNkBRM8fS1FDnvuLGV1mG3GMuK75I4Iss-SIvAvR62WdaAX1c2vqdZ92ypQfpLl8UZ6ey1nkJy6AxXS0sDJtFSgsPhcOzNFU8Y0InAdpoGC9ryzGTrZwH6MXyM-i8D-So3BXnZRvqgf3TKEAPKzlZUhIzERNBRIC6KxK0Qurql3zyucQV5ynnLOIB6jSy1pL1_6l4fPkonqMbg_HBvtzfHe49QTepV4WIgnHeQOvzs3P3FHy6uX5WKhJGn65ac38DH_pdOw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NTkJICMH4CgwwEtoLDTiO49qPYaMaBapq3dDeLH9lVEBarR3S9tdjO2mrwkDiIS_xOXJ8d77zne9ngFfC6EoUOUkZMSylyosxF1yllroA7SKIcSGg_3nIDk_o4LQ43QK2rIWJh_YjpGVcppenw97OvaGhfuNL_INpJtKrNzNb3YBt729ntAPbZTkYD9bRlYizhtsqGZzzaz6wYYkiYP91XuafhyV_y5hGQ9S_C3daDxKVzZjvwZard2Bv1EBQX3bR8bqiat5Fe2i0Bqe-3IHbTZwONeVH9-Fo5Je8tjoSraG_0bRCCplQ8xJCAqhW35xFM-9q_5hYdDAs0U9lQk4eqTM18S4mGpdH43R_-iUlD-Ck__54_zBt71lIjffXFmnV0xRbUnBFPK8UN94lVMqGlKzJc6V6xOXEZtozrrKkyg3vWaf9Pq8wwlFR5Q-hU09r9xhQwZ1imROUakVdQTWm2nfHWBnMNLYJZMs5l6YFIQ93YXyXMRmec9nwSXo-ycgneZXA61WfWQPB8U_qd4GVK8oAnx1fTM_PZCtO0hsoY3paWP_bNFNaBJAaXjGmeEWFLhLYXQqCbHV6Lv1eM6DdF5Ql8HLV7LUxpFhU7aYXkYYEyH2WJfCokZvVSHIqciywSKC3IVEbQ91sqSdfI-I3Z5zTjCfQXcreelh_n4on_0f-Am6ODvry04fhx6dwiwRNyYhfRXehszi_cM-887XQz1tN-wVcvSgi
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preclinical+evaluation+of+a+candidate+naked+plasmid+DNA+vaccine+against+SARS-CoV-2&rft.jtitle=npj+vaccines&rft.au=Lassauni%C3%A8re%2C+Ria&rft.au=Polacek%2C+Charlotta&rft.au=Gram%2C+Gregers+J.&rft.au=Frische%2C+Anders&rft.date=2021-12-20&rft.issn=2059-0105&rft.eissn=2059-0105&rft.volume=6&rft.issue=1&rft_id=info:doi/10.1038%2Fs41541-021-00419-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41541_021_00419_z
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2059-0105&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2059-0105&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2059-0105&client=summon